3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
enzalutamide
21
Magnetic Resonance Spectroscopy
21
apalutamide
17
Androgen Antagonists
14
Specimen Handling
13
Prednisone
13
Abiraterone Acetate
13
abiraterone
9
Docetaxel
9
Radiotherapy
8
Biopsy
8
darolutamide
7
Radiosurgery
7
Pluvicto
7
Nivolumab
7
cabazitaxel
6
Lutetium-177
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
Lutetium
5
radium Ra 223 dichloride
4
pembrolizumab
4
niraparib
4
gallium 68 PSMA-11
4
cabozantinib
4
bicalutamide
4
atezolizumab
4
Watchful Waiting
4
Surveys and Questionnaires
4
Standard of Care
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled